Gastro-oesophageal cancer is the third commonest cause of cancer death in the UK. Each year, there are approximately 16 500 new cases and over 13 000 deaths attributable to the disease. Overall survival is poor with the majority of patients presenting with advanced, inoperable disease and less than 15% surviving 5 years ([Cancer Research UK, Information Resource Centre, 2004](#bib6){ref-type="other"}). Although there have been improvements in survival following surgery ([Ando *et al*, 2000](#bib3){ref-type="other"}; [Hundahl *et al*, 2000](#bib14){ref-type="other"}; [Hofstetter *et al*, 2002](#bib13){ref-type="other"}; [von Rahden and Stein, 2004](#bib20){ref-type="other"}), for the majority of patients current treatment offers little in terms of improved survival. As a result quality of life in these patients is likely to be of considerable importance ([Aaronson, Bullinger and Ahmedzai, 1988](#bib2){ref-type="other"}; [Aaronson *et al*, 1993](#bib1){ref-type="other"}).

The European Organisation for Research and Treatment of Cancer have developed and validated the EORTC-QLQ-C30 questionnaire designed to assess the quality of life of cancer patients ([Aaronson *et al*, 1993](#bib1){ref-type="other"}). Disease-specific aspects of the questionnaire provide detailed information about the patients\' perception of their health. Moreover, it has been reported that, in a few studies, the EORTC QLQ-C30 measurement of quality of life may have prognostic value in patients with gastro-oesophageal cancer ([Conroy *et al*, 2006](#bib8){ref-type="other"}).

[Blazeby *et al*, (2001)](#bib4){ref-type="other"} reported that, in addition to age and TNM stage, physical function or emotional function had independent prognostic value in 92 patients with oesophageal cancer. However, treatment (whether or not the patient underwent surgery) was not included in the model ([Blazeby *et al*, 2001](#bib4){ref-type="other"}).

[Fang *et al* (2004)](#bib12){ref-type="other"} studied 110 patients with squamous oesophageal cancer and concluded that there was evidence to support the correlation of patient-reported quality of life scores with survival; therefore, pretreatment physical functioning might be a surrogate marker of an unrecognised biological prognostic factor. Although performance status was significant on univariate analysis, it was not significant on multivariate analysis; whereas physical functioning was significant ([Fang *et al*, 2004](#bib12){ref-type="other"}).

In contrast, in a study of more than 1000 patients with inoperable gastro-oesophageal cancer, entering three randomised clinical trials, [Chau *et al* (2004)](#bib7){ref-type="other"} reported that no aspect of the QLQ-C30 had independent prognostic value when performance status was considered. However, physical function, role function and global quality of life were associated with survival on univariate analysis. There were no survival differences among patients with oesophageal or gastric cancer ([Chau *et al*, 2004](#bib7){ref-type="other"}). However, this study was retrospective and included selected cohorts of patients.

Therefore, from the above it remains unclear whether any aspect of quality of life other than physical function has a role in predicting survival in an unselected cohort of patients with gastro-oesophageal cancer. The aim of the present study was to examine the relationship between quality of life (EORTC QLQ-C30), clinico-pathological characteristics and survival in patients with gastro-oesophageal cancer.

PATIENTS AND METHODS
====================

Patients
--------

Patients presenting with adenocarcinoma or squamous carcinoma of the gastric or oesophageal tract at the Royal Infirmary and Southern General Hospital, Glasgow between November 1997 and December 2002 (*n*=152) participated in a quality of life study, using the EORTC QLQ-C30 core questionnaire.

The extent of tumour spread was recorded using the TNM 5th edition classification ([Sobin and Wittekind, 1997](#bib19){ref-type="other"}). Tumours around the gastro-oesophageal junction were further classified according to tumour site, using the Siewert system; type 1 and 2 lesions of the gastro-oesophageal junction were designated as cancers of the oesophagus. Type 3 tumours of the cardia were designated as gastric cancers ([Siewert and Stein, 1998](#bib18){ref-type="other"}).

For gastric cancers, TNM stage I--III tumours were considered to be potentially amenable to curative surgical resection. For oesophageal cancers, TNM stage I--III tumours, excluding T4, were deemed to be potentially amenable to curative surgical resection. Patients who had stage 1 and 2 disease but whose performance status was poor or who had significant comorbidity were deemed not suitable for surgery and went forward for active palliative treatment or supportive care. There were 152 patients included in the study, 69 patients underwent surgery and 83 patients received active palliative treatment or supportive care.

The study was approved by the Research Ethics Committee of the Royal Infirmary and Southern General Hospital, Glasgow.

Methods
-------

Clinical and demographic variables were recorded at the patient\'s initial presentation and included age, sex, tumour type, site and length, TNM stage, ECOG performance status, weight loss and dysphagia.

Following diagnosis but prior to treatment the lead clinician approached patients as to whether they would participate in a study to examine their quality of life. If they gave informed consent they were given the EORTC QLQ-C30 questionnaire to complete.

Different aspects of quality of life were assessed using this cancer-specific 30-item questionnaire, which has six functional scales (physical, role, emotional, cognitive, social, global health status) and several questions relating to a range of physical symptoms ([Aaronson *et al*, 1993](#bib1){ref-type="other"}). Patients marked to what extent each statement applied to them. A number of patients were excluded because they were unlikely to understand the questionnaire either due to language, brain metastases, delirium or confusion. Neither age nor performance status were considered when offering the patient questionnaire. Few subjects were excluded (less than 10 patients) and therefore in those patients offered the questionnaire the bias was likely to be small.

Statistics
----------

Scoring algorithms have been produced by the EORTC Quality of Life Study Group. The sum of items in each category is added and the total divided by the number of questions in the category. A linear transformation is then undertaken to convert this to a percentage scale with a higher score representing a higher response level. Thus a high score for functional scale represents a high/healthy level of functioning. A high score for the global health status/quality of life represents a high quality of life. In contrast, a high score for the symptom scale represents a higher level of symptoms/problems ([Aaronson *et al*, 1993](#bib1){ref-type="other"}).

Data are presented as the median and range. Survival was determined from the time of biopsy proven diagnosis, and the end point for survival analysis was cancer-specific death. Patients were followed up at their clinic or endoscopy appointments and information on date and cause of death was checked with that received by the cancer registration system through the Registrar General (Scotland). Deaths up to the end of April 2007 were included in the analysis.

Univariate and multivariate survival analysis and calculation of hazard ratios (HR) were performed using a Cox regression model. For simplicity of presentation, a single hazard ratio was calculated for each ordered categorical variable, corresponding to the relative risk between adjacent categories. Hazard ratios for EORTC quality of life and symptom scores relate to a one percentage point increase in the score. Owing to the large number of covariates examined, only those that were significant on univariate analysis were included in the multivariate analysis, and only main effects were considered. The analysis was performed using a backward stepwise procedure to derive a final model of the variables that had a significant relationship with survival. To remove a variable from the model, the corresponding *P*-value had to be greater than 0.05. The proportional hazards assumption was checked using log minus log plots.

Comparison of the association between tumour site, TNM stage, treatment and the functional (physical, role, emotional, cognitive, social, global health status) and physical symptoms (fatigue, pain and appetite loss) scales of the EORTC-QLQ-C30 quality of life questionnaire was carried out using the *χ*^2^-test or Mann--Whitney *U*-test where appropriate. Analysis was performed using SPSS software (SPSS Inc. Chicago, IL, USA).

RESULTS
=======

Patient characteristics and cancer specific survival analysis of patients with gastro-oesophageal cancer (*n*=152) are shown in [Table 1](#tbl1){ref-type="table"}. The minimum follow-up period was 54 months or until date of death, the median follow-up for survivors was 81 months, one patient was lost to follow up and one patient withdrew from the study. During this period 106 (70%) patients died from their disease and 14 (9%) died from comorbid disease.

The majority of patients were over the age of 65 years (57%), male (68%) and had adenocarcinomas (84%). The majority of patients presented with weight loss (66%), had little or no dysphagia and a near normal performance status (ECOG-ps, 71%). The majority of patients had EORTC QLQ-C30 function scores above 50 (physical functioning 100%, role functioning 65%, emotional functioning 74%, cognitive functioning 83%, social functioning 79% and global quality of life 56%) and symptom scores below 50 (fatigue 69%, nausea/vomiting 85%, pain 86%, dyspnoea 79%, sleep disturbance 69%, appetite loss 64%, constipation 76%, diarrhoea 95% and financial difficulties 89%) and therefore had apparently normal quality of life ([Table 1](#tbl1){ref-type="table"}).

On univariate analysis, age (*P*\<0.01), tumour length (*P*\<0.0001), TNM stage (*P*\<0.0001), weight loss (*P*\<0.0001), dysphagia score (*P*\<0.001), performance status (*P*\<0.1) and treatment (*P*\<0.0001) were significantly associated with cancer-specific survival. EORTC QLQ-C30, physical functioning (*P*\<0.0001), role functioning (*P*\<0.001), cognitive functioning (*P*\<0.1), social functioning (*P*\<0.0001), global quality of life (*P*\<0.0001), fatigue (*P*\<0.0001), nausea/vomiting (*P*\<0.01), pain (*P*\<0.001), dyspnoea (*P*\<0.0001), appetite loss (*P*\<0.0001) and constipation (*P*\<0.01) were also significantly associated with cancer-specific survival.

On multivariate analysis, tumour stage (*P*\<0.001), treatment (*P*\<0.0001) and appetite loss (*P*\<0.0001) were significantly independent predictors of cancer-specific survival. The relationship between appetite loss and cancer-specific survival in patients with gastro-oesophageal cancer is shown in [Figure 1](#fig1){ref-type="fig"}.

When appetite loss was rescaled so that the four categories were represented by an integer score of 0 to 3 (rather than a percentage score), the unadjusted hazard ratio comparing adjacent categories was 2.06 (95% CI 1.72--2.48, *P*\<0.0001). When adjusted for stage and treatment, it was 1.72 (95% CI 1.41--2.08, *P*\<0.0001). When adjusted for stage, treatment and remaining clinico-pathological variables, it was 2.07 (95% CI 1.61--2.67, *P*\<0.0001). When adjusted for stage, treatment, remaining clinico-pathological variables and quality of life and symptom scores, it was 2.03 (95% CI 1.40--2.94, *P*=0.0002).

In the present study C-reactive protein concentrations, at the time of quality of life assessment, were available in 94 patients (57 patients \<10 mg l^−1^, 37 patients \>10 mg l^−1^) and were significantly associated with poorer cancer-specific survival (*P*\<0.0001). Therefore we included C-reactive protein in addition to TNM stage, treatment and appetite loss in the multivariate survival model. TNM stage (HR 1.37, 95% CI 1.01--1.87, *P*=0.0426), treatment (HR 3.67, 95% CI 1.74--7.75, *P*=0.0006), appetite loss (HR 1.02, 95% CI 1.01--1.03, *P*\<0.0001) and C-reactive protein (HR 2.15, 95% CI 1.21--3.83, *P*=0.0091) were independently associated with cancer-specific survival.

The relationship between tumour site, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer is shown in [Table 2](#tbl2){ref-type="table"}. Compared with the gastric cancer patients, oesophageal cancer patients were older (*P*\<0.01), had more dysphagia (*P*\<0.001) and a poorer ECOG-ps (*P*\<0.05). In terms of quality of life, compared with the gastric cancer patients, oesophageal cancer patients had higher emotional functioning (*P*\<0.01), cognitive functioning (*P*\<0.05), less nausea and vomiting (*P*\<0.05).

The relationship between TNM stage and clinico-pathological and quality of life characteristics in patients with gastric-oesophageal cancer is shown in [Table 3](#tbl3){ref-type="table"}. With increasing TNM stage patients had greater weight loss (*P*\<0.01) and were less likely to have had surgery (*P*\<0.001). In terms of quality of life, with increasing TNM stage there was poorer physical functioning (*P*\<0.05), emotional functioning (*P*\<0.05), social functioning (*P*\<0.01) and global quality of life (*P*\<0.01). In terms of symptoms, with increasing TNM stage there was more fatigue (*P*\<0.01), appetite loss (*P*\<0.001), dyspnoea (*P*\<0.05) and constipation (*P*\<0.05).

The relationship between appetite loss, clinico-pathological characteristics and quality of life in patients with gastric-oesophageal cancer is shown in [Table 4](#tbl4){ref-type="table"}. Increasing appetite loss was associated with greater tumour length (*P*\<0.05), TNM stage (*P*\<0.001) and the operability of the tumour (*P*\<0.001). Also, increasing appetite loss was associated with weight loss (*P*\<0.001) and dysphagia (*P*\<0.001). In terms of quality of life, increasing appetite loss was associated with poorer physical (*P*\<0.001), role (*P*\<0.001), emotional (*P*\<0.01), cognitive (*P*\<0.01), social (*P*\<0.001) and global quality of life (*P*\<0.001) functioning. In terms of symptoms, with increasing appetite loss there was more fatigue (*P*\<0.01), nausea and vomiting (*P*\<0.001), pain (*P*\<0.001), sleep disturbance (\<0.05) and constipation (*P*\<0.001).

The relationship between systemic inflammatory response, as evidenced by elevated C-reactive protein, clinico-pathological and quality of life characteristics in patients with gastric-oesophageal cancer is shown in [Table 5](#tbl5){ref-type="table"}. An elevated C-reactive protein was associated with greater tumour length (*P*\<0.01), advanced TNM stage (*P*\<0.01) and the operability of the tumour (*P*\<0.001) and a poorer ECOG-ps (*P*\<0.05). In terms of quality of life, an elevated C-reactive protein was associated with poorer physical (*P*\<0.01), role (*P*\<0.05) and social (*P*\<0.05) functioning. In terms of symptoms, with an elevated C-reactive protein was associated with more fatigue (*P*\<0.01), pain (*P*\<0.05) and appetite loss (*P*\<0.01).

DISCUSSION
==========

In the present study tumour site was not associated with major differences in EORTC QLQ-C30 quality of life function or symptom scores. However, there were major differences in quality of life and symptom scores with increasing stage of disease. In particular, social functioning, fatigue, appetite loss and global quality of life were all impaired with increasing tumour stage.

As might be expected in view of these associations with tumour stage, the majority of quality of life and symptom scores predicted survival on univariate analysis. It was of interest, however, that appetite loss remained an independently significant prognostic factor even after adjustment for TNM stage and treatment. Furthermore, the predictive value of appetite loss was maintained even after adjustment for all other clinico-pathological variables and quality of life and symptom scores. Taken together the results of the present study highlight the importance of appetite loss as a presenting symptom in patients with gastro-oesophageal cancer.

Few studies have examined the relationship between aspects of quality of life and survival in patients with gastro-oesophageal cancer. The results of the present study are consistent with the report of [Fang *et al* (2004)](#bib12){ref-type="other"} who reported that appetite loss was associated with poorer survival in 110 patients with oesophageal cancer. However, the association was much weaker than that of the present study and was not significant in multivariate analysis. Furthermore, the follow-up period and the number of patients who died of their disease were not defined. [Blazeby *et al* (1995)](#bib5){ref-type="other"}, in a smaller study of 59 patients with oesophageal cancer, also reported that appetite loss was associated with poorer survival.

The basis of the relationship between appetite loss and poorer cancer-specific survival cannot be determined by the present cross sectional study. However, it was of interest that appetite loss was closely associated with nausea and vomiting, dysphagia and weight loss and therefore it may be that these symptoms result in appetite loss and the consequent loss of weight, which has long been recognised to impact on outcome ([Dewys *et al*, 1980](#bib11){ref-type="other"}).

A number of workers have implicated the systemic inflammatory response in this process ([Kotler, 2000](#bib15){ref-type="other"}; [MacDonald, 2007](#bib16){ref-type="other"}). [O\'Gorman *et al* (1988)](#bib17){ref-type="other"}, in a cross sectional study, showed that in addition to appetite loss and weight loss, the systemic inflammatory response was an important factor in determining patients\' quality of life (EORTC QLQ-C30) in gastro-intestinal cancer patients ([O\'Gorman *et al*, 1988](#bib17){ref-type="other"}). Therefore, it is of interest that two recent studies have shown that the presence of a systemic inflammatory response, as evidenced by an elevated C-reactive protein, predicts survival in both operable ([Crumley *et al*, 2006a](#bib9){ref-type="other"}) and inoperable ([Crumley *et al*, 2006b](#bib10){ref-type="other"}) gastro-oesophageal cancer patients. In the present study C-reactive protein concentrations, at the time of quality of life assessment, were available in 94 (62%) patients. Consistent with previous work an elevated C-reactive protein concentration was associated with increased appetite loss and when included in the multivariate analysis, an elevated C-reactive protein concentration was independently associated with poorer cancer-specific survival. However, even those patients without an elevated C-reactive protein concentration reported some appetite loss and the independent prognostic value of appetite loss remained, thus confirming the importance of appetite loss in the multifactorial nature of weight loss and poor outcome in these patients ([MacDonald, 2007](#bib16){ref-type="other"}).

In summary, in patients with gastro-oesophageal cancer, routinely used prognostic factors are based predominantly on clinical and pathological findings. The present study highlights the importance of quality of life (EORTC QLQ-C30) measures, in particular appetite loss, as prognostic factors in these patients.

![The relationship between appetite loss (None, A little, Quite a bit, Very much, from top to bottom) and cancer specific survival in patients with gastro-oesophageal cancer.](6604248f1){#fig1}

###### 

The relationship between clinico-pathological characteristics, quality of life and cancer-specific survival in patients with gastro-oesophageal cancer (*n*=152)

                                       **Patients (*n*=152)**   **Univariate analysis HR (95%CI)**   ***P*-value**   **Multivariate analysis HR (95%CI)**   ***P*-value**
  ----------------------------------- ------------------------ ------------------------------------ --------------- -------------------------------------- ---------------
  Age: (\<65/65--74/⩾75)                      66/56/30                  1.46 (1.14--1.89)               0.0033                                                     
  Sex: (male/female)                           104/48                   0.84 (0.55--1.30)               0.4377                                                     
  Tumour type: (adeno/squamous)                127/25                   1.40 (0.83--2.36)               0.2016                                                     
  Tumour site: (oesophagus/gastric)            70/82                    0.88 (0.60--1.29)               0.5163                                                     
  Tumour length: (\<5/510/\>10 cm)            60/70/12                  2.37 (1.71--3.27)              \<0.0001                                                    
  TNM stage: (I/II/III/IV)                  28/46/34/41                 2.29 (1.84--2.83)              \<0.0001               1.65 (1.25--2.18)               \<0.0004
  Weight loss: (no/yes)                        51/101                   3.08 (1.94--4.89)              \<0.0001                                                    
  Dysphagia score: (1/2/3/4/5)             81/23/32/15/1                1.37 (1.16--1.63)               0.0003                                                     
  ECOG: (0--1/2/3--4)                         108/38/6                  1.61 (1.14--2.27)               0.0069                                                     
  Treatment: (operable/inoperable)             69/83                    8.12 (5.06--13.03)             \<0.0001               5.29 (2.80--9.97)               \<0.0001
                                                                                                                                                                   
  EORTC QLQ-C30 (0--100)                   Median (range)                                                                                                          
  Physical functioning                     93 (66.7--100)               0.96 (0.94--0.98)               0.0001                                                     
  Role functioning                         66.7 (0--100)                0.99 (0.99--1.00)               0.0006                                                     
  Emotional functioning                     66.7 (0--100                1.00 (0.99--1.00)               0.1302                                                     
  Cognitive functioning                    83.3 (0--100)                0.99 (0.98--0.99)               0.0051                                                     
  Social functioning                       83.3 (0--100)                0.99 (0.98--0.99)              \<0.0001                                                    
  Global quality of life                    50 (0--100)                 0.98 (0.97--0.99)              \<0.0001                                                    
  Fatigue                                  33.3 (0--100)                1.02 (1.01--1.02)              \<0.0001                                                    
  Nausea and vomiting                      16.7 (0--100)                1.01 (1.00--1.02)               0.0067                                                     
  Pain                                     16.7 (0--100)                1.01 (1.01--1.02)               0.0002                                                     
  Dyspnoea                                   0 (0--100)                 1.01 (1.01--1.02)               0.0001                                                     
  Sleep disturbance                        33.3 (0--100)                1.00 (0.99--1.01)               0.1558                                                     
  Appetite loss                            33.3 (0--100)                1.02 (1.02--1.03)              \<0.0001               1.02 (1.01--1.03)               \<0.0001
  Constipation                             33.3 (0--100)                1.01 (1.00--1.02)               0.0007                                                     
  Diarrhoea                                  0 (0--100)                 1.00 (0.99--1.01)               0.9586                                                     
  Financial difficulty                       0 (0--100)                 1.01 (1.00--1.01)               0.0932                                                     

###### 

The relationship between tumour site, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer (*n*=152)

                                               **Gastric (*n*=82)**   **Oesophageal (*n*=70)**   ***P*-value**
  ------------------------------------------- ---------------------- -------------------------- ---------------
  Age: (\<65 years/ 65--74 years/⩾75 years)          41/29/12                 25/27/18              0.0041
  Sex: (male/female)                                  53/29                    51/19                 0.279
  Type: (squamous/adeno)                               1/81                    24/46                \<0.001
  Tumour length: (\<5 cm/5--10 cm/\>10 cm)           33/33/7                  27/37/5                0.724
  Tumour stage: (I/II/III/IV)                      22/13/18/28               6/33/16/13              0.528
  Dysphagia score: (1/2/3/4/5)                      64/9/8/1/0               17/14/24/1             \<0.001
  Weight loss: (yes/no)                               53/29                    48/22                 0.610
  ECOG: (0--1/2/3--4)                                64/17/1                  44/21/5                0.018
  Treatment: (operable/inoperable)                    38/44                    31/39                 0.800
                                                                                                        
  EORTC QLQ-C30 (0--100)                          Median (range)           Median (range)               
  Physical functioning                           93.3 (66.7--100)         93.3 (66.7--100)           0.733
  Role functioning                                66.7 (0--100)            66.7 (0--100)             0.923
  Emotional functioning                           66.7 (0--100)            83.3 (0--100)             0.007
  Cognitive functioning                           83.3 (0--100)            83.3 (0--100)             0.038
  Social functioning                              83.3 (0--100)             75 (0--100)              0.964
  Global quality of life                           50 (0--100)              50 (0--100)              0.284
  Fatigue                                         33.3 (0--100)            22.2 (0--100)             0.077
  Nausea and vomiting                             16.7 (0--100)              0 (0--100)              0.036
  Pain                                            16.7 (0--100)            16.7 (0--100)             0.716
  Dyspnoea                                        33.3 (0--100)              0 (0--100)              0.123
  Sleep disturbance                               33.3 (0--100)            33.3 (0--100)             0.360
  Appetite loss                                   33.3 (0--100)            33.3 (0--100)             0.624
  Constipation                                    33.3 (0--100)            33.3 (0--100)             0.031
  Diarrhoea                                         0 (0--100)               0 (0--100)              0.802
  Financial difficulty                              0 (0--100)              0 (0--66.7)              0.098

###### 

The relationship between TNM stage and clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer (*n*=149)

                                               **TNM I (*n*=28)**   **TNM II (*n*=46)**   **TNM III (*n*=34)**   **TNM IV (*n*=41)**   ***P*-value**
  ------------------------------------------- -------------------- --------------------- ---------------------- --------------------- ---------------
  Age: (\<65 years/ 65--74 years/⩾75 years)         15/12/1               23/21/2                18/9/7               18/13/10             0.482
  Sex: (male/female)                                 17/11                 33/13                 20/14                  31/10              0.387
  Tumour type: (squamous/adeno)                       2/26                 13/33                  6/28                  4/37               0.576
  Tumour site: (oesophagus/gastric)                   6/22                 33/13                 16/18                  13/28              0.528
  Tumour length: (\<5 cm/5--10 cm/\>10 cm)           19/7/0               21/22/3               10/19/3                8/22/6             \<0.001
  Weight loss: (yes/no)                              14/14                 29/17                 23/11                  34/7               0.004
  Dysphagia score: (1/2/3/4/5)                     22/3/3/0/0           20/10/9/7/0            14/5/9/5/1            23/5/10/3/0           0.130
  ECOG: (0--1/2/3--4)                                22/6/0               33/11/2                27/6/1                24/15/2             0.099
  Treatment: (operable/inoperable)                    25/3                 26/20                 15/19                  1/40              \<0.001
                                                                                                                                              
  EORTC QLQ-C30 (0--100)                         Median (range)       Median (range)         Median (range)        Median (range)             
  Physical functioning                          93.3 (73.3--100)      100 (66.7--100)       100 (73.3--100)       86.7 (66.7--100)         0.023
  Role functioning                               66.7 (0--100)         66.7 (0--100)         66.7 (0--100)           50 (0--100)           0.058
  Emotional functioning                         66.7 (8.3--100)        75 (25--100)          83.3 (0--100)          58.3 (0--100)          0.042
  Cognitive functioning                          83.3 (50--100)      83.3 (33.3--100)       83.3 (16.7--100)         75 (0--100)           0.042
  Social functioning                            100 (33.3--100)        83.3 (0--100)         66.7 (0--100)           50 (0--100)           0.002
  Global quality of life                        66.7 (8.3--100)        66.7 (0--100)         50 (16.7--100)         41.7 (0--100)          0.001
  Fatigue                                        27.8 (0--66.7)       22.2 (0--88.9)         33.3 (0--100)          55.6 (0--100)          0.002
  Nausea and vomiting                            16.7 (0--100)          0 (0--100)           16.7 (0--100)          16.7 (0--100)          0.553
  Pain                                           16.7 (0--66.7)        16.7 (0--100)         33.3 (0--100)          16.7 (0--100)          0.098
  Dyspnoea                                       16.7 (0--100)          0 (0--100)             0 (0--100)           33.3 (0--100)          0.014
  Sleep disturbance                                 (0--100)           33.3 (0--100)         33.3 (0--100)          66.7 (0--100)          0.689
  Appetite loss                                    0 (0--100)          33.3 (0--100)         33.3 (0--100)          66.7 (0--100)         \<0.001
  Constipation                                   33.3 (0--66.7)        16.7 (0--100)           0 (0--100)           33.3 (0--100)          0.013
  Diarrhoea                                        0 (0--100)           0 (0--100)            0 (0--33.3)            0 (0--66.7)           0.601
  Financial difficulty                            0 (0--66.7)           0 (0--100)            0 (0--66.7)            0 (0--100)            0.306

###### 

The relationship between appetite loss, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer (*n*=152)

                                               **Not at all (*n*=55)**   **A little (*n*=43)**   **Quite a bit (*n*=26)**   **Very much (*n*=28)**   ***P*-value**
  ------------------------------------------- ------------------------- ----------------------- -------------------------- ------------------------ ---------------
  Age: (\<65 years/ 65--74 years/⩾75 years)           27/18/10                 18/15/10                   8/15/3                    13/8/7               0.540
  Sex: (male/female)                                    43/12                    26/17                    15/11                      20/8                0.312
  Tumour type: (squamous/adeno)                         7/48                     5/38                      7/19                      6/22                0.138
  Tumour site: (oesophagus/gastric)                     25/30                    17/26                    15/11                     13/15                0.603
  Tumour length: (\<5 cm/5--10 cm/ \>10 cm)            27/20/4                  18/21/2                   9/15/2                    6/14/4               0.016
  TNM stage: (I/II/III/IV)                           16/17/13/8                8/17/9/9                  3/8/7/8                   1/4/5/16             \<0.001
  Weight loss: (yes/no)                                 26/29                    27/16                     22/4                      26/2               \<0.001
  Dysphagia score: (1/2/3/4/5)                       37/10/6/2/0              24/6/10/3/0               9/4/9/3/1                 11/3/7/7/0            \<0.001
  ECOG: (0--1/2/3--4)                                  39/14/2                  34/8/1                    18/7/1                    17/9/2               0.281
  Treatment: (operable/inoperable)                      35/20                    20/23                    11/15                      3/25               \<0.001
                                                                                                                                                            
  EORTC QLQ-C30 (0--100)                           Median (range)           Median (range)            Median (range)            Median (range)              
  Physical functioning                             100 (73.3--100)          100 (73.3--100)          86.7 (66.7--100)           80 (66.7--100)          \<0.001
  Role functioning                                  100 (0--100)             66.7 (0--100)            58.3 (0--100)             33.3 (0--100)           \<0.001
  Emotional functioning                            75 (73.3--100)            66.7 (0--100)           83.3 (8.3--100)            58.3 (0--96.7)           0.003
  Cognitive functioning                           83.3 (16.7--100)           83.3 (0--100)            83.3 (50--100)             66.7(0--100)            0.001
  Social functioning                                100 (0--100)             83.3 (0--100)            66.7 (0--100)              50 (0--100)            \<0.001
  Global quality of life                          66.7 (16.7--100)            50 (0--100)            45.8(16.7--100)            29.1 (0--66.7)          \<0.001
  Fatigue                                          11.1 (0--88.9)           33.3 (0--83.2)            33.3 (0--100)            77.7 (22.2--100)         \<0.001
  Nausea and vomiting                                0 (0--100)              16.7 (0--100)            16.7 (0--100)             41.7 (0--100)           \<0.001
  Pain                                              16.7 (0--100)           16.7 (0--83.3)            33.3 (0--100)              25 (0--100)            \<0.001
  Dyspnoea                                           0 (0--66.7)              0 (0--100)                0 (0--100)               50 (0--100)            \<0.001
  Sleep disturbance                                  0 (0--100)              33.3 (0--100)            33.3 (0--100)             33.3 (0--100)            0.044
  Constipation                                       0 (0--100)              33.3 (0--100)            33.3 (0--100)             66.7 (0--100)           \<0.001
  Diarrhoea                                          0 (0--100)               0 (0--66.7)               0 (0--100)                0 (0--100)             0.512
  Financial difficulty                               0 (0--66.7)              0 (0--100)                0 (0--100)                0 (0--100)             0.296

###### 

The relationship between systemic inflammatory response, as evidenced by elevated C-reactive protein, clinico-pathological and quality of life characteristics in patients with gastric-oesophageal cancer (*n*=94)

                                              **CRP\<10 (*n*=57)**   **CRP\>10 (*n*=37)**   ***P*-value**
  ------------------------------------------ ---------------------- ---------------------- ---------------
  Age: (\<65 years/65--74 years/⩾75 years)          34/16/7                18/12/7              0.258
  Sex: (male/female)                                 38/19                  27/10               0.520
  Tumour type: (adeno/squamous)                       48/9                   30/7               0.695
  Tumour site: (oesophagus/gastric)                  23/34                  20/17               0.195
  Tumour length: (\<5 cm/5--10 cm/\>10 cm)          35/17/2                11/20/3              0.005
  Tumour stage: (I/II/III/IV)                      15/20/13/8             4/10/10/13            0.006
  Weight loss: (yes/no)                              31/16                  27/10               0.072
  Dysphagia score: (1/2/3/4/5)                    29/14/11/3/0           18/6/10/2/1            0.390
  ECOG: (0--1/2/3--4)                                52/5/0                27/10/0              0.019
  Treatment: (operable/inoperable)                   40/17                   8/29              \<0.001
                                                                                                   
  EORTC: (0--100)                                Median (range)         Median (range)             
  Physical functioning                           100 (73--100)         86.7 (66.7--100)         0.001
  Role functioning                               66.7 (0--100)          66.7 (0--100)           0.040
  Emotional functioning                          66.7 (0--100)          70.8 (0--100)           0.343
  Cognitive functioning                         83.3 (16.7--100)       83.3 (33.3--100)         0.875
  Social functioning                             83.3 (0--100)          66.7 (0--100)           0.045
  Global quality of life                         66.7 (0--100)           50 (0--100)            0.068
  Fatigue                                        33.3 (0--100)          44.4 (0--88.9)          0.003
  Nausea and vomiting                            16.7 (0--100)          16.7 (0--100)           0.152
  Pain                                           16.7 (0--100)          16.7 (0--100)           0.040
  Appetite loss                                  33.3 (0--100)          66.7 (0--100)           0.001
